Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 44Specimen Handling 38enzalutamide 30Nivolumab 30pembrolizumab 28Docetaxel 23Gemcitabine 22apalutamide 20Prednisone 20Biopsy 20Abiraterone Acetate 18Androgen Antagonists 17cabozantinib 14darolutamide 13abiraterone 13Radiotherapy 13Cisplatin 12enfortumab vedotin 11Radiation 11Ipilimumab 11Pluvicto 10erdafitinib 9belzutifan 9atezolizumab 9X-Rays 9Radiosurgery 9Mitomycin 9olaparib 8cabazitaxel 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
PF06821497 × Genitourinary × 30 days × Clear all
NCT06629779 2026-06-05

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07028853 2026-06-05

MEVPRO-3

Pfizer

Phase 3 Recruiting
1,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡